4,058
Views
3
CrossRef citations to date
0
Altmetric
Genetic Disease

Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis

, , , &
Pages 783-791 | Received 29 Mar 2022, Accepted 11 May 2022, Published online: 09 Jun 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ivo Abraham, Kenneth K. C. Lee & Mike Gregg. (2023) Journal of Medical Economics in review: high impact articles from 2022. Journal of Medical Economics 26:1, pages 303-307.
Read now

Articles from other publishers (2)

Rachael Taylor, Deborah Sullivan, Penny Reeves, Nicola Kerr, Amy Sawyer, Emma Schwartzkoff, Andrew Bailey, Christopher Williams & Alexis Hure. (2023) A Scoping Review of Economic Evaluations to Inform the Reorientation of Preventive Health Services in Australia. International Journal of Environmental Research and Public Health 20:12, pages 6139.
Crossref
Landon Z MarshallRachel EspinosaCatherine I StarnerPatrick P Gleason. (2023) Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis. Journal of Managed Care & Specialty Pharmacy 29:6, pages 599-606.
Crossref